Currently available therapies such as niacin and PCSK9 inhibitors such as Repatha (evolocumab) and Praluent (alirocumab) can reduce Lp (a) levels, but their impact is modest. Another challenge in ...

Elevated lipoprotein(a) levels can slowly block the arteries, increasing the likelihood of cardiovascular disease. Since no treatment is currently available for this condition, it is essential to ...

Brigham and Women's Hospital investigators link very high lipoprotein(a) with a higher 30-year risk of major cardiovascular ...

Dear Dr. Roach: I'm a healthy 50-year-old woman. I asked my doctor to test me for Lipoprotein(a) after reading about it. My level was high, at 41 mg/dL. My doctor told me that it didn't need to be ...

Contemporary guidelines do not generally endorse universal screening ...

Find out how lipoprotein(a) screening identifies women at long term cardiovascular risk and supports earlier prevention ...

Elevated levels of lipoprotein (a) is a genetic disease that causes cardiovascular disease. Steven Nissen, M.D., addresses why it’s important to find treatments for this genetic risk factor.

Assessing lipoprotein(a) (Lp[a]) levels in US adults, both with and without atherosclerotic cardiovascular disease (ASCVD), was previously an uncommon practice but exhibited a notable surge post-2018, ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...